CTAs vs. INDs
Understand the Purpose, Content, and Procedural Similarities and Differences between the CTA and IND.
Deciding to submit a Clinical Trial Authorisation (CTA) or Investigational New Drug Application (IND) is a significant milestone in developing a new drug, biologic, or vaccine.
Suppose the goal of a development program is to initiate clinical trials within European member states, the United Kingdom, or North America. In that case, strategic consideration to how, when, and whether to submit a CTA or IND is critically important.
Read our infographic to learn the purpose, content, and procedural similarities and differences between the CTA and IND.